Anti-CD20 therapies have transformed the treatment landscape of Multiple Sclerosis (MS), offering highly effective disease control through targeted B-cell depletion. As these therapies are increasingly used early in the disease course and maintained over many years, understanding their long-term efficacy, safety, and optimal use has become essential for clinical practice.

In this webinar, Celia Oreja-Guevara and Patrick Vermersch review the latest evidence on anti-CD20 therapies, including ocrelizumab, ofatumumab, rituximab, and ublituximab. Drawing from pivotal clinical trials, extension studies, and real-world data, they discuss long-term outcomes, safety considerations, treatment personalization strategies, and emerging challenges in managing patients receiving prolonged B-cell depletion therapy.

Learning Objectives

By participating in this webinar, learners will be able to:

• Review the role of B cells in Multiple Sclerosis pathophysiology and the rationale for anti-CD20 therapies.
• Compare the mechanisms of action and key characteristics of currently available anti-CD20 agents.
• Evaluate long-term efficacy data from clinical trials and extension studies, including effects on relapses, disability progression, MRI activity, and disease control.
• Assess long-term safety outcomes, including infection risk, malignancy risk, and immunoglobulin monitoring.
• Discuss practical approaches to treatment optimization, including dosing interval extension, treatment continuation, and individualized patient management.
• Apply current evidence to support treatment decisions across different patient populations with relapsing forms of Multiple Sclerosis.

Long-term Efficacy and Safety of Anti-CD20 Therapies

Please subscribe to watch.

Log-in on subscribe

Find out more about the speakers:

Vice-president of Research in the fields of Life and Health Sciences at the University of Lille

Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid

Funding

This webinar was organized with the financial support of Neuraxpharm.

Neuraxpharm has not been involved in the elaboration of the presentations.

We value your opinion.

How likely are you to recommend this material to a friend or colleague?

Selected Value: 1

Give a score from 1 (= not at all likely) to 10 (extremely likely)

Tell us what you think or ask a question to the expert.

Give your opinion on the quality of the material and send us your comments, questions or feedback. Where relevant, we'll liaise with the Expert and get back to you.

Email

If you have submitted a question above, leave your email so we can get back to you.

a or Tell

Submit